BPC-157 10mg · Research brief

BPC 159 vs BPC 157: Salt Forms and What COAs Show

Real Peptides Research TeamEditorial

Updated September 28, 20269 min read

59 WORDS

Short answer

Search BPC-159 in the indexed scientific literature and you get nothing back. Search BPC-157 and you get decades of preclinical papers, a CAS number, and a molecular formula, which is the single most useful fact in any BPC 159 vs BPC 157 comparison. Our team fields this question constantly from researchers cross-checking vendor listings, and the pattern never changes.

Key takeaways

BPC-157 is a fifteen-amino-acid pentadecapeptide with CAS 137525-51-0, molecular formula C62H98N16O22, and a free-base molecular weight of approximately 1419.5 g/mol.
BPC-159 has no published sequence, no CAS registry entry, and no indexed peer-reviewed studies, which makes analytical verification impossible.
The real distinction behind most BPC 157 vs 159 searches is salt form: trifluoroacetate, acetate, or arginate.
Residual TFA from HPLC purification is a documented confounder in cell-based assays, which is why acetate salt is the standard choice for in vitro research.
Arginine's counterion mass of roughly 174.2 g/mol against acetate's 60.05 means arginate powder carries less peptide per milligram of gross weight.
A usable COA is lot-specific and shows HPLC area-percent purity, a confirming mass spectrum, the declared counterion, and a lot number matching the vial.
All BPC-157 material supplied by Real Peptides is for laboratory research use only and is not an approved drug product.

Our team fields this question constantly from researchers cross-checking vendor listings, and the pattern never changes. The confusion isn't really about two different peptides. It's about salt forms, loose labelling, and product pages that never show their analytical data.

What is the difference between BPC 159 and BPC 157?

BPC-157 is a characterised synthetic pentadecapeptide, fifteen amino acids, CAS 137525-51-0, with an extensive preclinical literature. BPC-159 has no published sequence, no CAS registry entry, and no indexed peer-reviewed studies. It appears almost exclusively in vendor marketing. In practice, most BPC 159 vs BPC 157 searches are really questions about acetate versus arginate salt forms of the same molecule.

The common oversimplification is that these are two rival compounds with different potencies. They aren't. One is a defined molecule with a mass spectrum behind it, and the other is a name. What follows covers the verified chemistry of BPC-157, what the acetate, arginate, and trifluoroacetate salt forms actually change in a laboratory setting, and which documents let you confirm identity before a purchase order goes out.

Two compounds, only one with a molecular formula

BPC-157 is a synthetic pentadecapeptide: fifteen residues in the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, molecular formula C62H98N16O22, free-base molecular weight of roughly 1419.5 g/mol, CAS 137525-51-0. The designation stands for Body Protection Compound, and the sequence corresponds to a fragment of a protein isolated from human gastric juice. Published preclinical work, much of it produced by the research group led by Predrag Sikiric, describes activity in rodent models across tendon, gastrointestinal, and vascular tissue. Mechanistic papers in that body of literature point toward VEGFR2 (vascular endothelial growth factor receptor 2) signalling, the nitric oxide system, and the FAK-paxillin pathway involved in fibroblast migration. Studies also report that the peptide resists degradation in human gastric juice over extended periods, which is why oral research formats keep reappearing.

BPC-159 has none of this. No published sequence. No CAS registry entry. No indexed studies under that designation. Where the name shows up, it is typically framed as a newer or more stable version of BPC-157, with no analytical data attached. We've reviewed a lot of these listings. The tell is always identical: a name, a price, a stock counter, and no mass spectrum. In a straight BPC 157 vs BPC 159 comparison, one side has verifiable chemistry and the other has copywriting.

Acetate, arginate, TFA: what the counterion actually changes

Most of what gets marketed as a difference between products is a difference in salt form. Solid-phase peptide synthesis followed by reverse-phase HPLC purification in trifluoroacetic acid leaves the finished peptide as a trifluoroacetate (TFA) salt by default. Converting it to an acetate salt requires a separate ion-exchange or repeated-lyophilisation step, which costs money, which is exactly why a lot of inexpensive material is quietly still TFA salt. That matters at the bench: residual TFA is a documented confounder in cell-based assays and can suppress cell viability independently of the peptide under study. So the honest answer on BPC-157 acetate vs BPC-157 supplied as trifluoroacetate is that the acetate form is generally the cleaner choice for in vitro work.

Arginate applies the same principle with a different counterion, arginine in place of acetic acid. Vendors position BPC-157 arginate salt as the more stable or more orally robust option. As far as we can locate, no published peer-reviewed head-to-head pharmacokinetic comparison of BPC-157 arginate vs acetate exists.

Here is the part nearly every product page skips: counterion mass. Arginine weighs roughly 174.2 g/mol against acetate's 60.05 and TFA's 114.02. At the same labelled gross vial weight, a heavier counterion means less peptide in the vial. And the moment the salt dissolves, the counterion dissociates. The peptide in solution is chemically identical. BPC-157 arginate salt vs BPC-157 acetate is a question about the powder, not about the molecule.

What a certificate of analysis shows that a product page can't

A lot-specific certificate of analysis is the only document connecting the vial in front of you to a verified identity. Four elements belong on it: RP-HPLC purity expressed as area percent, with research-grade specifications commonly written at 98% or higher; a mass spectrum by ESI-MS or MALDI-TOF confirming an observed mass consistent with roughly 1419.5 g/mol; the stated salt form and counterion; and a lot number plus date that match the vial label. Water content by Karl Fischer and net peptide content are the two extras separating a serious COA from a decorative one, because lyophilised peptides are hygroscopic and gross weight is never peptide weight.

Then run the identity check: CAS 137525-51-0, the fifteen-residue sequence, the formula C62H98N16O22. If a listing can't produce those three, there is nothing to verify. This is precisely why BPC-159 fails at the procurement stage rather than the research stage. On handling, lyophilised material held at -20°C and protected from light and moisture holds specification longest, and temperature excursions degrade peptide integrity in ways visual inspection will never reveal.

Real Peptides synthesises in small batches with exact amino-acid sequencing and publishes certificates of analysis for review, so researchers comparing forms can read the specification for BPC-157 next to the background material in our BPC-157 research overview or across the wider research peptide catalog. What we don't provide is dosing, reconstitution, or administration guidance in any form, because these are research-use-only compounds and not approved drug products. This article is educational and describes laboratory research only.

BPC 159 vs BPC 157: Form and Documentation Comparison

This table compares the two salt forms of BPC-157 that researchers actually receive against the marketed BPC-159 label. The comparison is built on what can be verified from documentation, not on efficacy claims.

Attribute	BPC-157 acetate salt	BPC-157 arginate salt	BPC-159 as marketed	Bottom Line
Verifiable identity	CAS 137525-51-0, formula C62H98N16O22, mass confirmable near 1419.5 g/mol	Same peptide identity, arginine counterion declared on the COA	No published sequence, no CAS entry, no indexed literature	Only BPC-157 in either salt form can be analytically confirmed before purchase
Counterion and peptide load	Acetate at roughly 60.05 g/mol adds the least non-peptide mass	Arginine at roughly 174.2 g/mol adds more mass per vial at equal gross weight	Unknown, since no salt form is disclosed	Compare net peptide content, never gross vial weight
Published research base	Extensive rodent preclinical literature, largely from one research group	Same underlying peptide literature, no head-to-head PK study located	None under that designation	The literature belongs to the molecule, not to a salt form or a rebrand
Suitability for cell-based assays	Preferred, since residual TFA confounding is removed by ion exchange	Acceptable, though arginine load should be recorded as an assay variable	Unusable, since identity cannot be established	Acetate is the default choice for in vitro work
Regulatory position	Research use only; FDA has placed BPC-157 in Category 2 of its bulk substances list for compounding, and WADA lists it among prohibited non-approved substances	Identical regulatory position, salt form changes nothing	Undefined substance with no regulatory record	Neither form is an approved drug product in any jurisdiction

What If: Sourcing and Identity Scenarios

What if a vendor lists BPC-159 with no sequence or CAS number?

Treat it as an unidentified substance and don't purchase it. Without a declared sequence, a CAS reference, and a mass spectrum, there is no way to confirm what is in the vial, which means any downstream result is uninterpretable and unpublishable. Some sellers using the BPC-159 name are shipping ordinary BPC-157, some are shipping something else entirely, and neither possibility can be distinguished from the listing alone. Ask for a lot-specific certificate of analysis first. Silence in response to that request is the answer.

What if the label just says BPC-157 10mg with no salt form stated?

Assume trifluoroacetate salt until documentation proves otherwise. TFA is the default output of reverse-phase HPLC purification, and converting to acetate is an additional processing cost that suppliers generally advertise when they've paid for it. For cell culture work this matters, because residual trifluoroacetate can affect viability readouts independently of the compound under investigation. A COA that names the counterion, rather than leaving it blank, is a reasonable minimum standard.

What if two lots of BPC-157 behave inconsistently in the same assay?

Compare the two certificates of analysis side by side before questioning the experimental design. Differences in net peptide content, residual water by Karl Fischer, counterion identity, and HPLC area-percent purity all change the actual quantity of peptide delivered at an identical weighed mass. Lyophilised peptide is hygroscopic, so a vial opened repeatedly in humid conditions gains water weight that dilutes every subsequent measurement. Lot-to-lot documentation is what makes this diagnosable rather than mysterious.

What if a protocol was validated on acetate and the new material is arginate?

Record the salt form as an explicit variable and recalculate from net peptide content rather than gross vial weight. The dissolved peptide is the same molecule, so the primary structural chemistry doesn't change, but the arginine counterion contributes additional mass and introduces free arginine into the preparation once dissociated. In sensitive cell-based systems, that added arginine is worth controlling for. Our team has seen more apparent potency discrepancies traced back to counterion accounting than to synthesis quality.

The unglamorous truth about peptide analog naming

Here's the honest answer: BPC-159 is a marketing designation, not a characterised compound. Sequential numbering implies a research lineage that doesn't exist in the published record, and the number 159 carries no more chemical meaning than a randomly chosen one would. Anyone framing BPC 159 vs BPC 157 as a next-generation upgrade is making a claim that no sequence, no mass spectrum, and no peer-reviewed paper supports. The genuinely useful comparison is the boring one: acetate versus arginate versus trifluoroacetate salt of a single, well-defined pentadecapeptide, and which supplier will hand you the paperwork to prove it.

The BPC 159 vs BPC 157 question tends to dissolve the moment someone asks for a certificate of analysis, because documentation is where invented compounds stop existing. That's the durable habit worth building. Not memorising which salt form is fashionable this year, but treating CAS number, sequence, observed mass, and declared counterion as the four fields that must be filled before anything enters a freezer. Chemistry that can't be verified isn't a research material. It's a guess with a label on it.

References

Peer-reviewed sources on BPC-157 indexed in PubMed, listed for research context. Real Peptides supplies BPC-157 for laboratory research use only.

Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS journal : the musculoskeletal journal of Hospital for Special Surgery, 2025. PMID 40756949. doi:10.1177/15563316251355551
Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals (Basel, Switzerland), 2025. PMID 40005999. doi:10.3390/ph18020185
Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Current reviews in musculoskeletal medicine, 2025. PMID 40789979. doi:10.1007/s12178-025-09990-7
Stable Gastric Pentadecapeptide BPC 157 and Intestinal Anastomoses Therapy in Rats-A Review. Pharmaceuticals (Basel, Switzerland), 2024. PMID 39204186. doi:10.3390/ph17081081
From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management. International journal of molecular sciences, 2026. PMID 41898733. doi:10.3390/ijms27062876
BPC-157 and Its Novel Hybrid Analogs as Inhibitors of Acetylcholinesterase. International journal of molecular sciences, 2026. PMID 42278509. doi:10.3390/ijms27114984
Protective effects of BPC 157 in rats with experimentally induced lower extremity ischemia-reperfusion injury. Scientific reports, 2026. PMID 42204242. doi:10.1038/s41598-026-55449-1
Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Joint diseases and related surgery, 2026. PMID 42542926. doi:10.52312/jdrs.2026.2951

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

BPC-157 is a defined synthetic pentadecapeptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, CAS 137525-51-0, and an extensive preclinical literature. BPC-159 has no published amino acid sequence, no CAS registry entry, and no indexed peer-reviewed studies under that name. The practical difference is that one compound can be analytically verified by mass spectrometry and the other cannot.

There is no publicly documented chemistry for BPC-159. It does not appear in indexed scientific literature, has no CAS registry number, and no supplier we have reviewed publishes a sequence or mass spectrum for it. Where the name appears, it functions as a product label rather than a characterised molecule, and material sold under it cannot be confirmed as anything specific.

A vial labelled simply BPC-157 is usually the trifluoroacetate (TFA) salt, because TFA is the default counterion left behind by reverse-phase HPLC purification. BPC-157 acetate has undergone an additional ion-exchange step that replaces trifluoroacetate with acetate. The peptide sequence is identical in both cases, but the acetate form removes residual TFA, which is a known confounder in cell viability and cell-based assays.

There is no published peer-reviewed head-to-head pharmacokinetic comparison of BPC-157 arginate vs acetate that we can locate, so claims of superiority are vendor positioning rather than documented findings. Arginine's counterion mass of roughly 174.2 g/mol is substantially heavier than acetate's 60.05 g/mol, meaning arginate powder contains less peptide per milligram of gross weight. Once dissolved, the counterion dissociates and the peptide itself is the same molecule.

Check that the COA is lot-specific and that the lot number and date match the vial label exactly. It should show RP-HPLC purity as an area percentage, a mass spectrum by ESI-MS or MALDI-TOF confirming an observed mass consistent with about 1419.5 g/mol, and the declared salt form. Water content by Karl Fischer and net peptide content are the two additional fields that indicate a genuinely rigorous analysis rather than a template document.

Real Peptides supplies BPC-157 as a research-use-only compound to researchers and laboratories, not as a drug product for human or veterinary use. Research-use-only material is intended for laboratory investigation under appropriate institutional oversight. Buyers should confirm that their own institutional and jurisdictional requirements permit acquisition of the compound before ordering.

Three variables drive most of the spread: salt form, net peptide content, and analytical testing. Converting a trifluoroacetate salt to acetate requires an extra ion-exchange and lyophilisation step that adds real manufacturing cost, and lot-specific HPLC plus mass spectrometry testing adds more. A listing priced far below the market usually reflects gross vial weight rather than net peptide, untested material, or both.

No. BPC-157 is not an approved drug product in any jurisdiction and is supplied for laboratory research use only. The FDA placed BPC-157 into Category 2 of its bulk drug substances list relating to compounding, and the World Anti-Doping Agency lists it among prohibited non-approved substances. Neither the acetate nor the arginate salt form changes that regulatory position.

No. Because these are research-use-only compounds rather than approved drug products, we do not provide dosing, reconstitution, administration, or protocol guidance of any kind. What we do publish is the analytical documentation researchers need for identity and purity: HPLC purity, mass confirmation, declared counterion, and lot-specific certificates of analysis. Concentration is a matter of milligrams per millilitre arithmetic that each laboratory determines under its own protocols.

Lyophilised peptide holds its specification longest when stored at -20°C, protected from light, and kept sealed against moisture. BPC-157 powder is hygroscopic, so repeated opening in humid conditions adds water weight that skews every subsequent mass measurement. Temperature excursions degrade peptide integrity in ways that visual inspection of the powder will not reveal, which is why documented cold-chain handling matters more than appearance.

BPC-159 listings should be excluded outright, since there is no sequence or CAS number to verify against. Between the remaining options, acetate salt BPC-157 is the conventional choice for in vitro work because residual trifluoroacetate interferes with cell-based readouts. If arginate material is used, the arginine counterion should be logged as an experimental variable and calculations should be based on net peptide content rather than gross vial weight.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA